These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15625075)

  • 1. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
    Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
    J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
    Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
    J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
    Shiota A; Yamamoto K; Ohishi M; Tatara Y; Ohnishi M; Maekawa Y; Iwamoto Y; Takeda M; Rakugi H
    Hypertens Res; 2010 Apr; 33(4):298-307. PubMed ID: 20186149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
    Daniel C; Schaub K; Amann K; Lawler J; Hugo C
    Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
    Usui HK; Shikata K; Sasaki M; Okada S; Matsuda M; Shikata Y; Ogawa D; Kido Y; Nagase R; Yozai K; Ohga S; Tone A; Wada J; Takeya M; Horiuchi S; Kodama T; Makino H
    Diabetes; 2007 Feb; 56(2):363-72. PubMed ID: 17259380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
    Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
    Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Leipner C; Grün K; Müller A; Buchdunger E; Borsi L; Kosmehl H; Berndt A; Janik T; Uecker A; Kiehntopf M; Böhmer FD
    Cardiovasc Res; 2008 Jul; 79(1):118-26. PubMed ID: 18326555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
    Kelly DJ; Chanty A; Gow RM; Zhang Y; Gilbert RE
    J Am Soc Nephrol; 2005 Jun; 16(6):1654-60. PubMed ID: 15843473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor, transforming growth factor-beta, and connective tissue growth factor in a porcine bronchial model of obliterative bronchiolitis.
    Alho HS; Maasilta PK; Vainikka T; Salminen US
    Exp Lung Res; 2007 Aug; 33(6):303-20. PubMed ID: 17694440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
    Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
    J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress.
    Zhang M; Hagiwara S; Matsumoto M; Gu L; Tanimoto M; Nakamura S; Kaneko S; Gohda T; Qian J; Horikoshi S; Tomino Y
    Metabolism; 2006 Dec; 55(12):1590-8. PubMed ID: 17142129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of {alpha}8-integrin aggravates podocyte injury in experimental diabetic nephropathy.
    Hartner A; Cordasic N; Menendez-Castro C; Volkert G; Yabu JM; Kupraszewicz-Hutzler M; Rascher W; Hilgers KF
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1151-7. PubMed ID: 20826576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy.
    Savikko J; Taskinen E; Von Willebrand E
    Transplantation; 2003 Apr; 75(8):1147-53. PubMed ID: 12717194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.
    Yoshiji H; Noguchi R; Kuriyama S; Ikenaka Y; Yoshii J; Yanase K; Namisaki T; Kitade M; Masaki T; Fukui H
    Am J Physiol Gastrointest Liver Physiol; 2005 May; 288(5):G907-13. PubMed ID: 15618280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of MK2 signalling in vivo inhibits small Hsp phosphorylation but not diabetic nephropathy.
    Park JK; Ronkina N; Höft A; Prohl C; Menne J; Gaestel M; Haller H; Meier M
    Nephrol Dial Transplant; 2008 Jun; 23(6):1844-53. PubMed ID: 18182404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
    Dai C; Yang J; Bastacky S; Xia J; Li Y; Liu Y
    J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
    Hamada Y; Fukagawa M
    Kobe J Med Sci; 2007; 53(1-2):53-61. PubMed ID: 17582205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.